Showing 1661-1670 of 1692 results for "".
- Phase 3 Clinical Trial of Continuous Subcutaneous Carbidopa/Levodopa Initiatedhttps://practicalneurology.com/news/phase-3-clinical-trial-of-continuous-subcutaneous-carbidopalevodopa-initiated/2469005/The phase 3 Boundless study (NCT04006210) has been initiated to investigate ND0612 (Mitsubishi Tanabe Pharma America, Jersey City, NJ) for Parkinson’s disease (PD). The ND0612 compound is a continuous subcutaneous formulation of
- Patient Selection and Team-Based Care Essential in PFO Closure for Secondary Stroke Preventionhttps://practicalneurology.com/news/patient-selection-and-team-based-care-essential-in-pfo-closure-for-secondary-stroke-prevention/2468985/Meta-analysis reported in the journal Cardiology, shows that across 6 randomized clinical trials, closure of patent foramen ovale (PFO) is superior to medical treatment alone for prevention of secondary stroke in individuals who had cry
- Phase 2b Study Ending for Sublingual Ketamine for Acute Painhttps://practicalneurology.com/news/phase-2b-study-ending-for-sublingual-ketamine-for-acute-pain/2468909/The Food and Drug Administration (FDA) has scheduled an end-of-phase 2 clinical trial meeting for a sublingual formulation of racemic ketamine (Wafermine; iX Biopharma, Singapore) for treatment of moderate-to-severe acute pain. The therapy contains R and S isomers of ketamine in e
- Tofersen for Treatment of Familial Amyotrophic Lateral Sclerosishttps://practicalneurology.com/news/experimental-drug-shows-promise-for-treating-genetic-form-of-als/2468879/An early-stage trial for tofersen (BIIB067; Biogen, Cambridge, MA) an investigational drug for amyotrophic lateral sclerosis (ALS), showed that the drug is linked to slower progression of a form of the disease caused by mutations in the superoxide dismutase 1 (SOD1) gene. Results of the stud
- New Drug Application Novel for Oral Fumarate Accepted by Food and Drug Administrationhttps://practicalneurology.com/news/new-drug-application-novel-for-oral-fumarate-accepted-by-food-and-drug-administration/2468826/The Food and Drug Administration (FDA) has accepted an application for diroximel fumarate (BIIB098; Alkermes, Waltham, MA and Biogen, Cambridge, MA) for the treatment of relapsing forms of multiple sclerosis (MS). eb. 25, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: B
- Warnings and Advisories Issued to 17 Companies for Products Illegally Marketed as Treatment for Alzheimer's Diseasehttps://practicalneurology.com/news/warnings-and-advisories-issued-to-17-companies-for-products-illegally-marketed-as-treatment-for-alzheimers-disease/2468836/The Food and Drug Administration (FDA) posted 12 warning letters and 5 online advisory letters issued to 17 foreign and domestic companies that illegally sell more than 58 products. Many of the products claim to treat or cure Alzheimer’s disease and other serious diseases and conditions.&nb
- Nasally-Delivered CGRP Antagonist for Migraine Achieves Phase 1 Clinical Trial Targetshttps://practicalneurology.com/news/nasally-delivered-cgrp-antagonist-for-migraine-achieves-phase-1-clinical-trial-targets/2468852/In a phase 1 clinical trial, it was shown that intranasal delivery of a third-generation calcitonin gene-related peptide antagonist reached therapeutic levels in treated participants. The drug, BHV-3500 (Biohaven, New Haven, CT) is the first intranasal formulation of a CGRP antagonist and is bein
- Wearable Device Provides Data for Treatment of Parkinson's Diseasehttps://practicalneurology.com/news/wearable-device-provides-data-for-treatment-of-parkinsons-disease/2468851/A study to be published in the Journal of Parkinson’s Disease and made available in prepress form shows that a wearable device (Personal KinetiGraph, Global Kinetics Corporation Lt
- Sumatriptan Nasal Spray Approved for Acute Migraine Treatmenthttps://practicalneurology.com/news/sumatriptan-nasal-spray-approved-for-acute-migraine-treatment/2468860/The Food and Drug Administration has approved sumatriptan nasal spray 10mg (Tosymra; Promius Pharma, Princeton, NJ) for acute treatment of migraine with or without aura in adults. This formulation of sumatriptan uses technology that allows oral, buccal, dermal, and intranasal drug delivery of non
- Wireless Spinal Cord Stimulator Provides Relief from Chronic Painhttps://practicalneurology.com/news/wireless-spinal-cord-stimulator-provides-relief-from-chronic-pain/2468869/Clinical trial results showed that the world’s first wireless, fully programmable neuromodulation system (Freedom SCS System; Stimwave Technologies, Pompano Beach, FL) provided significant relief for patients suffering from chronic back and leg pain. In the trial, 92% of patie